Bradford C. Dickerson

Jun 24, 2024 | academic.oup.com | Bradford C. Dickerson

Neurodegenerative dementia syndromes, such as Primary Progressive Aphasias (PPA), have traditionally been diagnosed based in part on verbal and nonverbal cognitive profiles. Debate continues about whether PPA is best divided into three variants and also regarding the most distinctive linguistic features for classifying PPA variants.

Jan 5, 2024 | frontiersin.org | Bradford C. Dickerson

Massachusetts General Hospital, Harvard Medical School, United StatesThe final, formatted version of the article will be published soon. Receive an email when it is updatedYou just subscribed to receive the final version of the articleVisual naming ability reflects semantic memory retrieval and is a hallmark deficit of Alzheimer's disease (AD). Naming impairment is most prominently observed in the late-onset amnestic and logopenic variant Primary Progressive Aphasia (lvPPA) syndromes.

Dec 19, 2023 | neuro.psychiatryonline.org | Kaloyan S. Tanev |David Caplan |Bradford C. Dickerson

Access content To read the fulltext, please use one of the options below to sign in or purchase access. Personal login Institutional Login Sign in via OpenAthens Register for access Purchase Save for later Item saved, go to cart Not a subscriber? Subscribe Now / Learn MorePsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources.

Jun 6, 2023 | mdedge.com | Bradford C. Dickerson

The field of neurodegenerative dementias, particularly Alzheimer’s disease (AD), has been revolutionized by the development of imaging and cerebrospinal fluid biomarkers and is on the brink of a new development: emerging plasma biomarkers. Research now recognizes the relationship between the cognitive-behavioral syndromic diagnosis (that is, the illness) and the etiologic diagnosis (the disease) – and the need to consider each separately when developing a diagnostic formulation.

Jun 5, 2023 | medscape.com | Bradford C. Dickerson

The field of neurodegenerative dementias, particularly Alzheimer’s disease (AD), has been revolutionized by the development of imaging and cerebrospinal fluid biomarkers and is on the brink of a new development: emerging plasma biomarkers. Research now recognizes the relationship between the cognitive-behavioral syndromic diagnosis (ie, the illness) and the etiologic diagnosis (the disease) — and the need to consider each separately when developing a diagnostic formulation.